Education
School ¡X Major ¡X Degree | Duration |
---|---|
»O¥_Âå¾Ç¤j¾Ç ¡X ÃľǨt(²¦) ¡X ³Õ¤h Doctorate, School of Pharmacy, Taipei Medical University |
2000/09 ¡X 2008/06 |
»O¥_Âå¾Ç°| ¡X ÃľǬã¨s©Ò(²¦) ¡X ºÓ¤h Master, , |
1998/09 ¡X 2000/06 |
»O¥_Âå¾Ç°| ¡X ÃľǨt(²¦) ¡X ¾Ç¤h Bachelor, , |
1993/09 ¡X 1998/06 |
Intramural Experience
Office/Department/Institute | Position | Duration |
---|---|---|
ÃľǨt School of Pharmacy | Professor | 2024/08/01 ¡X |
ÃľǨt School of Pharmacy | Associate Professor | 2021/02/01 ¡X 2024/07/31 |
ÃľǨt School of Pharmacy | Assistant Professor | 2018/02/01 ¡X 2021/01/31 |
Extramural Experience
DEPNO | Position- Office/Department/Institute | Duration |
---|---|---|
¤¸°öÂå¨Æ¬ì§Þ¤j¾Ç¥Íª«¬ì§Þº[»sÃħ޳N¨t | °Æ±Ð±Â | 1040201 ¡X 1070131 |
¤¸°öÂå¨Æ¬ì§Þ¤j¾Ç¥Íª«¬ì§Þº[»sÃħ޳N¨t | §U²z±Ð±Â | 0990901 ¡X 1040131 |
Discipline
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
¤fµÄ½Ã¥Í¡BÃÄùÛ«O°·¹«~¡B¤¤¯óÃÄ¡B¥ÍÂå§÷®Æ¡B¹B°ÊÂå¾Ç
Oral hygiene, cosmeceutical health food, Chinese herbal medicine, biomedical materials, sports medicine.
Area(s) of Expertise & Research
ÃĪ«¾¯«¬³]p»P¶Ç»¼¨t²Î¡BÃľ¯¾Ç¡B¤u·~ÃľǡB±±ÄÀ»s¾¯¾ÇÃĪ«¾¯«¬¶}µo³]p¡BÃĪ«¶Ç»¼¨t²Î¡BÃľ¯¾Ç¡B¤u·~ÃľǡB½Õ±±ÄÀ¾¯«¬¶}µo
Development and Design of drug dosage form, Drug delivery system, Pharmaceutics, Industrial pharmacy, Development of modified release dosage forms (extended-release, prolonged-release, controlled-release, slow release and sustained-release)
Publication
NO | Publication |
---|---|
1 | ¶Wµªi»²§U®ø¸Ñªº¥Ò»Ä²æ²ÓM¥~°ò½è©M¿}´ß¯À©`¦ÌÅÖºû½Æ¦X¤ô¾®½¦»P´I§t¦å¤pªOªº¦å¼ßµ²¦X¥Î©ó¿}§¿¯f¶Ë¤fªvÀø Composite Hydrogels of Ultrasound-Assisted-Digested Formic Acid-Decellularized Extracellular Matrix and Sacchachitin Nanofibers Incorporated with Platelet-Rich Plasma for Diabetic Wound Treatment |
2 | ¨Ï¥Î¦@¸ü©ó°ò©ó§ZÁC¯×ªº¦Û©`¦Ì¨Å¤Æ¹w¿@ÁYª« (LBSNEP) ¤¤ªº¦N¦è¥LÀØ©Mµµ§ü¾J¤fªA¸`«ßªvÀø¯ØŦÀù¡C Oral metronomic therapy of pancreatic cancer with gemcitabine and paclitaxel co-loaded in lecithin-based Self-Nanoemulsifying preconcentrate (LBSNEP). |
3 | Development of a Swellable and Floating Gastroretentive Drug Delivery System (sfGRDDS) of Ciprofloxacin Hydrochloride Development of a Swellable and Floating Gastroretentive Drug Delivery System (sfGRDDS) of Ciprofloxacin Hydrochloride |
4 | ³z¹L²K¥[ßm¤þ¥ÒÅÖºû¯À©M³z©ú½è»Ä¨Ïªy¬¥¨F©i·»½¦¨ã¦³ì¦ì¾®½¦©Ê©MÂH½¤ÂHªþ©Ê¡AÀ³¥Î©µªø¨¤½¤º¢¯d©MÃĪ«¿é°e Poloxamer sols endowed with in-situ gelability and mucoadhesion by adding hypromellose and hyaluronan for prolonging corneal retention and drug delivery |
5 | ¥ì¥ß´À±d»P¹p©¬Åð¯À©`¦Ì¨Å¤fªA¨Ö¥Î¨ó¦P¼W±j¯ØŦÀùÀø®Ä Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer |
6 | COVID-19 ¬Ì]±µºØ»P±aª¬¯p¯lªºÃöÁp¡G¨t²Îµû»ù©M²Î¦X¤ÀªR Association of COVID-19 vaccination with herpes zoster: a systematic review and meta-analysis |
7 | 利¥Î卵ÁC¯×°ò½è²V¦X»E¦Xª«·LM(lbMPMs)來´£¤É«p¦µ×ô©M¤ì蘭¾Jªº·»¸Ñ度©M¥ÍÅé¥i¥Î率 Honokiol/Magnolol-loaded Self-assembling Lecithin-based Mixed Polymeric Micelles (lbMPMs) for Improving Solubility to Enhance Oral Bioavailability |
8 | ¥H¤@Áç²£»s TEMPO ®ñ¤Æªº sacchachitin ©`¦ÌÅÖºû (TOSCNFs)±´°Q¼W±j°©¦A¥Í¥Î¤ä¬[ One-pot fabrication of sacchachitin for production of TEMPO-oxidized sacchachitin nanofibers (TOSCNFs) utilized as scaffolds to enhance bone regeneration |
9 | Rhizochitosan ªº»s³Æ©Mªí¼x¤Î¨ä»P¦å¤pªO¿@ÁYª«µ²¦X¹ï«P¶i¶Ë¤f¡¦X Fabrication and characterization of Rhizochitosan and its incorporation with platelet concentrates to promote wound healing |
10 | CPT11»PP-¿}³J¥Õ/CYP 3A4Âù¥\¯à§í»s¾¯³q¹L¦Û¯Ç¦Ì¨Å¤Æ¯Ç¦Ì¨Åµ²¦XGº¢¯d§Þ³N´£°ª¹ï¯Ø¸¢Àùªº¤fªA¥ÍÅé¥i¥Î²v©MÀø®Ä CPT11 with P-glycoprotein/CYP 3A4 dual-function inhibitor by self-nanoemulsifying nanoemulsion combined with gastroretentive technology to enhance the oral bioavailability and therapeutic efficacy against pancreatic adenocarcinomas |
11 | ·s«¬¥i¿±µÈ©Mº}¯B¦¡Gº¢¯dÃĪ«»¼°e¨t²Î¡]sfGRDDS¡^ªº»s³Æ©M¯S©Êªí¼xÀ³¥Î©ó´£ª@¥§¬¥´À¥§ªº¤fªA¥ÍÅé¥i¥Î²v Preparation and Characterization of a Novel Swellable and Floating Gastroretentive Drug Delivery System (sfGRDDS) for Enhanced Oral Bioavailability of Nilotinib |
12 | TEMPO®ñ¤Æ´X¤B¦hÁÞÅé©`¦ÌÅÖºû¡]TOSCNFs¡^µ²¦X¦å¤pªO¦å¼ß¡]PRP¡^ªvÀø°®²´¯g TEMPO-Oxidized Sacchachitin Nanofibers (TOSCNFs) Combined with Platelet-Rich Plasma (PRP) for Management of Dry Eye Syndrome |
13 | Preparation and Characterization of Chemically TEMPO-oxidized and Mechanically Disintegrated Sacchachitin Nanofibers (SCNF) for Enhanced Diabetic Wound Healing Preparation and Characterization of Chemically TEMPO-oxidized and Mechanically Disintegrated Sacchachitin Nanofibers (SCNF) for Enhanced Diabetic Wound Healing |
14 | µw¯×°ò»E¤A²m¨ÈÓi»P½è²É½Æ¦X§@¬°¤H¦å²M¥Õ³J¥Õ©`¦Ì²É¤l®Ö¤ß¥H«D¦@»ùµ²¦XCRISPR / Cas9½è²É©ÎsiRNA¡A¥Î©ó§K¬ÌªvÀø¯}Ãa©Î¨IÀqPD-L1ªí²{ Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy |
Project
NO |
YEAR ¡X Source ¡X No ¡X Type
Project Name
|
Duration |
---|---|---|
1 |
113 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC113-2221-E-037-003 ¡X 1 Ó¤H«¬
¶}µo¦P®É¨ã¦³Âù®ÄÄÀ©ñ(³t®Ä»Pªø®ÄÄÀ©ñ)¤§ªü¥ß?Ðüª`®g¾¯³B¤è³]p©MÃĪ«°Ê¤O¾Ç¬ã¨s( )
|
2024/08/01 ~ 2025/07/31 |
2 |
112 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC112-2221-E-037-002 ¡X 1 Ó¤H«¬
«D¦¬ÁY«¬·Å±Ó·P©Ê»E¨Å»Ä¥Ì¾J»Äì¦ì¤ô½¦ÅéÀ³¥Î©ó¥Ö¤U±±ÄÀÂù¯S²§©Êanti- PSMA/anti-CD3±µ¦X§ÜÅé( )
|
2023/08/01 ~ 2024/07/31 |
3 |
111 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST111-2221-E-037-004 ¡X 1 Ó¤H«¬
¤fªA¦Û¨Å¤Æ·L¦Ì¨Å¾¯¥]¸üCPT-11¤Îrapamycin«P¶i¯ØŦÀùªvÀøªº¨ó¦P§@¥Î( )
|
2022/08/01 ~ 2023/09/30 |
4 |
109 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2320-B-037-018 ¡X 1 Ó¤H«¬
·s¦¡¦Û©`¦Ì¨Å¤ÆGº¢¯dÃĪ«»¼°e¨t²Î¨ó¦PP-ÁÞ³J¥Õ©M²ÓM¦â¯À(3A4)Âù¥\¯à§í¨î¾¯´£¤ÉIrinotecan¤fªA¥ÍÅé¥i¥Î²v»PªvÀø®Ä¯à¬ã¨s( )
|
2020/08/01 ~ 2021/07/31 |
5 |
108 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST109-2813-C-037-001-E ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
109¦~«×¤j±M¾Ç¥Í¬ã¨spµe-¶À³Í羣(ÃľÇ3)( )
|
2020/07/01 ~ 2021/02/28 |